<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="the occipital cortex, followed by temporary neuronal silencing. During a" exact="migraine" post="attack, increased expression of inflammatory mediators, along with a"/>
 <result pre="receptor antagonist (IL-1RN), following CSD in a mouse model of" exact="familial hemiplegic migraine" post="type 1 (FHM-1). We show here that the expression"/>
 <result pre="(IL-1RN), following CSD in a mouse model of familial hemiplegic" exact="migraine" post="type 1 (FHM-1). We show here that the expression"/>
 <result pre="researchers to better understand the development of the disease and" exact="aids" post="in the search for new therapeutic strategies in migraine."/>
 <result pre="aids in the search for new therapeutic strategies in migraine." exact="migraine" post="IL-1RN cortical spreading depression mouse model 1. Introduction Migraine"/>
 <result pre="events may also play a role in the pathogenesis of" exact="migraine" post="[ 7, 8]. In particular, much attention has been"/>
 <result pre="role of immune-system hormones, named cytokines, to the pathogenesis of" exact="migraine" post="[ 9]. Based on preclinical and clinical studies, the"/>
 <result pre="contribute to the initiation of cell-mediated autoimmune diseases such as" exact="rheumatoid arthritis," post="type 1 diabetes, multiple sclerosis, and Guillain-Barré syndrome ["/>
 <result pre="cell-mediated autoimmune diseases such as rheumatoid arthritis, type 1 diabetes," exact="multiple sclerosis," post="and Guillain-Barré syndrome [ 10, 11, 13]. Anti-inflammatory cytokines"/>
 <result pre="15, 16, 17]. Sometimes, such as in the case of" exact="systemic lupus erythematosus," post="it seems that the combined action of Th1/Th2 cytokines"/>
 <result pre="16, 17]. Sometimes, such as in the case of systemic" exact="lupus erythematosus," post="it seems that the combined action of Th1/Th2 cytokines"/>
 <result pre="that blood levels of IL-1ra are augmented during attacks of" exact="multiple sclerosis" post="and are further augmented from the treatment of the"/>
 <result pre="have been found [ 23, 24, 25]. The association between" exact="migraine" post="and the interleukin-1 receptor antagonist variable number tandem repeat"/>
 <result pre="inflammation in the trigeminal nerve territory is often observed during" exact="migraine" post="attacks [ 32], so the acute administration of corticosteroids"/>
 <result pre="has been tested to block pain [ 33]. Familial hemiplegic" exact="migraine" post="type 1 (FHM-1) is a monogenic type of migraine"/>
 <result pre="hemiplegic migraine type 1 (FHM-1) is a monogenic type of" exact="migraine" post="with aura caused by mutations in the CACNA1A gene"/>
 <result pre="3B). 4. Discussion Many studies have shown a relationship between" exact="migraine" post="and inflammation [ 51, 52]. Neurogenic inflammation is characterized"/>
 <result pre="degranulation [ 51]. In particular, it has been proposed that" exact="migraine" post="may be associated with an inflammation of the meninges,"/>
 <result pre="inflammation of the meninges, especially the dura mater. During a" exact="migraine" post="attack, an idiopathic activation of the trigeminal sensory afferents"/>
 <result pre="been tested as potential therapeutic strategies in the treatment of" exact="migraine" post="[ 51]. The main current therapy for migraine is"/>
 <result pre="treatment of migraine [ 51]. The main current therapy for" exact="migraine" post="is based on triptans [ 53], which have been"/>
 <result pre="have been found to be either unaltered or reduced in" exact="migraine" post="patients as compared to healthy controls. Moreover, during a"/>
 <result pre="migraine patients as compared to healthy controls. Moreover, during a" exact="migraine" post="attack, the serum concentrations of IL-1β, IL-6, IL-8, and"/>
 <result pre="type 2 cytokines IL-4 and IL-5 decrease [ 54]. Interestingly," exact="migraine" post="seems to be associated with immune-inflammatory and atopic diseases"/>
 <result pre="Th1- or Th2-dominant responses, such as Inflammatory Bowel Disease and" exact="asthma" post="[ 54]. Many studies have already observed that CSD"/>
 <result pre="variety of diseases (e.g., autoimmunity [ 59, 60, 61, 62]," exact="cancer" post="[ 63, 64, 65, 66], hepatic [ 67, 68],"/>
 <result pre="studies [ 21, 22, 70, 71]. However, its role in" exact="migraine" post="is still largely unexplored. In a previous study, significantly"/>
 <result pre="of IL-1RN, TGF-β1, and MCP-1 in the cerebrospinal fluid of" exact="migraine" post="patients as compared to controls were found [ 72]."/>
 <result pre="[ 74]. Indeed, a role for the IFN pathway in" exact="migraine" post="has been described [ 44]. We may speculate that"/>
 <result pre="may speculate that compensatory mechanisms may be working constantly in" exact="migraine" post="patients via the reciprocal regulation of pro- and anti-inflammatory"/>
 <result pre="contribute to the vasodilatation and to the swelling mechanism underlying" exact="migraine" post="and nasal congestion, which represents one of the most"/>
 <result pre="most common symptoms [ 75]. The role of inflammation in" exact="migraine" post="is further supported by the therapeutic effects of non-steroidal"/>
 <result pre="drugs (NSAIDs), currently recommended as the first-line medications for acute" exact="migraine" post="attacks, as they improve both pain and breathing ["/>
 <result pre="symptoms, quality of life, and disability, and to reduce monthly" exact="migraine" post="days [ 78, 79, 80, 81]. This study may"/>
 <result pre="gene expression of pro- and anti-inflammatory cytokines in a mouse" exact="migraine" post="model. In particular, we focus on the expression of"/>
 <result pre="Sex differences in the epidemiology, clinical features, and pathophysiology of" exact="migraine" post="Lancet Neurol. 2017 16 76 87 10.1016/S1474-4422(16)30293-9 27836433 3."/>
 <result pre="P. Olesen J. Prevalence and sex-ratio of the subtypes of" exact="migraine" post="Int. J. Epidemiol. 1995 10.1093/ije/24.3.612 7672904 4. collab: Headache"/>
 <result pre="version) Cephalalgia 2013 10.1177/0333102413485658 5. Lauritzen M. Pathophysiology of the" exact="migraine" post="aura: The spreading depression theory Brain 1994 117 Pt"/>
 <result pre="Y. Role of cortical spreading depression in the pathophysiology of" exact="migraine" post="Neurosci. Bull. 2014 30 812 822 10.1007/s12264-014-1471-y 25260797 7."/>
 <result pre="7. Longoni M. Ferrarese C. Inflammation and excitotoxicity: Role in" exact="migraine" post="pathogenesis Neurol. Sci. 2006 10.1007/s10072-006-0582-2 8. Edvinsson L. Haanes"/>
 <result pre="Raj V. Liam C.K. Relationship between various cytokines implicated in" exact="asthma" post="Hum. Immunol. 2019 10.1016/j.humimm.2019.04.018 15. Nicoletti F. Mancuso G."/>
 <result pre="(TGF-beta1) are elevated in both relapsing remitting and chronic progressive" exact="multiple sclerosis" post="(MS) patients and are further augmented by treatment with"/>
 <result pre="Circulating serum levels of IL-1ra in patients with relapsing remitting" exact="multiple sclerosis" post="are normal during remission phases but significantly increased either"/>
 <result pre="M. Müller N. Förderreuther S. Straube A. Decreased sTNF-RI in" exact="migraine" post="patients? Cephalalgia 2003 10.1046/j.1468-2982.2003.00453.x 25. Covelli V. Munno I."/>
 <result pre="Exaggerated spontaneous release of tumor necrosis factor-alpha/cachectin in patients with" exact="migraine" post="without aura Acta Neurol. (Napoli) 1990 12 257 263"/>
 <result pre="Cytokine polymorphism in patients with migraine: Some suggestive clues of" exact="migraine" post="and inflammation Pain Med. 2010 10.1111/j.1526-4637.2009.00791.x 20113413 27. Skaper"/>
 <result pre="Moskowitz M.A. Neurogenic inflammation in the pathophysiology and treatment of" exact="migraine" post="Neurology 1993 43 Suppl. S3 S16 S20 8389008 29."/>
 <result pre="10.1523/JNEUROSCI.6440-10.2011 32. Friedman M.H. Local inflammation as a mediator of" exact="migraine" post="and tension-type headache Headache 2004 10.1111/j.1526-4610.2004.04143.x 33. Rowe B.H."/>
 <result pre="controlled trial of intravenous dexamethasone to prevent relapse in acute" exact="migraine" post="headache Headache 2008 10.1111/j.1526-4610.2007.00959.x 34. Van Den Maagdenberg A.M.J.M."/>
 <result pre="Mohrenweiser H.W. Bulman D.E. Ferrari M. et al. Familial hemiplegic" exact="migraine" post="and episodic ataxia type-2 are caused by mutations in"/>
 <result pre="Bulman D.E. Ferrari M. et al. Familial hemiplegic migraine and" exact="episodic ataxia" post="type-2 are caused by mutations in the Ca2+ channel"/>
 <result pre="Der Kaa J. Plomp J.J. et al. A Cacna1a knockin" exact="migraine" post="mouse model with increased susceptibility to cortical spreading depression"/>
 <result pre="20824453 38. Tfelt-Hansen P.C. Koehler P.J. One hundred years of" exact="migraine" post="research: Major clinical and scientific observations from 1910 to"/>
 <result pre="10.4103/0972-2327.182302 52. Ramachandran R. Neurogenic inflammation and its role in" exact="migraine" post="Semin. Immunopathol. 2018 40 301 314 10.1007/s00281-018-0676-y 29568973 53."/>
 <result pre="53. Johnston M.M. Rapoport A.M. Triptans for the management of" exact="migraine" post="Drugs 2010 70 1505 1518 10.2165/11537990-000000000-00000 20687618 54. Oliveira"/>
 <result pre="M.F.P. Unbalanced plasma TNF-α and IL-12/IL-10 profile in women with" exact="migraine" post="is associated with psychological and physiological outcomes J. Neuroimmunol."/>
 <result pre="Berman N.E.J. Cortical spreading depression and gene regulation: Relevance to" exact="migraine" post="Ann. Neurol. 2002 10.1002/ana.10158 58. Urbach A. Bruehl C."/>
 <result pre="cell biomarkers for predicting the response of patients with relapsing-remitting" exact="multiple sclerosis" post="to natalizumab treatment Mol. Med. Rep. 2019 20 678"/>
 <result pre="Preclinical evaluation of the PI3K/Akt/mTOR pathway in animal models of" exact="multiple sclerosis" post="Oncotarget 2018 9 8263 8277 10.18632/oncotarget.23862 29492193 62. Fagone"/>
 <result pre="Toll-like receptor 4 activation and in a murine model of" exact="systemic lupus erythematosus" post="Immunology 2014 142 10.1111/imm.12267 63. Presti M. Mazzon E."/>
 <result pre="receptor 4 activation and in a murine model of systemic" exact="lupus erythematosus" post="Immunology 2014 142 10.1111/imm.12267 63. Presti M. Mazzon E."/>
 <result pre="M. et al. Identification of novel chemotherapeutic strategies for metastatic" exact="uveal melanoma" post="Sci. Rep. 2017 7 44564 10.1038/srep44564 28303962 65. Basile"/>
 <result pre="al. Differential modulation and prognostic values of immune-escape genes in" exact="uveal melanoma" post="PLoS ONE 2019 14 e0210276 10.1371/journal.pone.0210276 30653520 66. Mangano"/>
 <result pre="with the CO-releasing molecule CORM-A1, in a murine model of" exact="autoimmune hepatitis" post="J. Cell. Physiol. 2018 233 4156 4165 10.1002/jcp.26223 29034470"/>
 <result pre="the CO-releasing molecule CORM-A1, in a murine model of autoimmune" exact="hepatitis" post="J. Cell. Physiol. 2018 233 4156 4165 10.1002/jcp.26223 29034470"/>
 <result pre="Evaluation of the changes in the nasal cavity during the" exact="migraine" post="attack J. Craniofac. Surg. 2014 10.1097/SCS.0b013e31827c80b1 76. Aukerman G."/>
 <result pre="Aukerman G. Knutson D. Miser W.F. Management of the acute" exact="migraine" post="headache Am. Fam. Physician 2002 66 2123 2130 12484694"/>
 <result pre="Y.Y. Chen W.H. et al. Medical treatment guidelines for acute" exact="migraine" post="attacks Acta Neurol. Taiwan. 2017 26 78 96 29250761"/>
 <result pre="H. Neeb L. Reuter U. Erenumab and galcanezumab in chronic" exact="migraine" post="prevention: Effects after treatment termination J. Headache Pain 2019"/>
 <result pre="Subgroup analyses of efficacy by high versus low frequency of" exact="migraine" post="headaches in phase 3 studies (EVOLVE-1 &amp;amp; EVOLVE-2) J."/>
 <result pre="Cohen J.M. Yeung P.P. Fremanezumab for the preventive treatment of" exact="migraine" post="Expert Opin. Biol. 2019 1 9 10.1080/14712598.2019.1627323 82. Neven"/>
</results>
